Snowball logo
logo
MMTZ

MindMaze Therapeutics Holding SA

MMTZF • OTCMKTS
$0.194$0.00  (0%)
Estimate
Beta
1.529
About the company
Ticker
MMTZF
ISIN
Country
Switzerland
Sector (GICS)
Other
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Frequently asked questions

What sector does MindMaze Therapeutics Holding SA (MMTZF) operate in?

MindMaze Therapeutics Holding SA belongs to the Other sector and operates in the industry.

What is MindMaze Therapeutics Holding SA (MMTZF) current stock price?

As of the latest data, MindMaze Therapeutics Holding SA stock price is $0.19, with a previous close of $0.19.

Does MindMaze Therapeutics Holding SA (MMTZF) pay dividends?

No. MindMaze Therapeutics Holding SA does not pay a dividend.

What is MindMaze Therapeutics Holding SA (MMTZF) beta (volatility) score?

MindMaze Therapeutics Holding SA has a beta of 1.529, suggesting it is more volatile than the market.